| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PDP |
| Uniprot No | Q9P0J1 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-537aa |
| 氨基酸序列 | MPAPTQLFFPLIRNCELSRIYGTACYCHHKHLCCSSSYIPQSRLRYTPHPAYATFCRPKENWWQYTQGRRYASTPQKFYLTPPQVNSILKANEYSFKVPEFDGKNVSSILGFDSNQLPANAPIEDRRSAATCLQTRGMLLGVFDGHAGCACSQAVSERLFYYIAVSLLPHETLLEIENAVESGRALLPILQWHKHPNDYFSKEASKLYFNSLRTYWQELIDLNTGESTDIDVKEALINAFKRLDNDISLEAQVGDPNSFLNYLVLRVAFSGATACVAHVDGVDLHVANTGDSRAMLGVQEEDGSWSAVTLSNDHNAQNERELERLKLEHPKSEAKSVVKQDRLLGLLMPFRAFGDVKFKWSIDLQKRVIESGPDQLNDNEYTKFIPPNYHTPPYLTAEPEVTYHRLRPQDKFLVLATDGLWETMHRQDVVRIVGEYLTGMHHQQPIAVGGYKVTLGQMHGLLTERRTKMSSVFEDQNAATHLIRHAVGNNEFGTVDHERLSKMLSLPEELARMYRDDITIIVVQFNSHVVGAYQNQE |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于PDP(磷酸二酯酶结构域蛋白)重组蛋白研究的3篇代表性文献示例(注：部分内容为模拟概括，实际文献需通过学术数据库查询)：
1. **文献名称**：*Expression and Purification of Recombinant PDP Domain Protein in E. coli*
**作者**：Smith J, et al.
**摘要**：研究报道了在大肠杆菌中高效表达PDP结构域重组蛋白的优化方法，通过亲和层析纯化获得高纯度蛋白，并验证其磷酸二酯酶活性。
2. **文献名称**：*Structural Analysis of PDP Recombinant Protein by X-ray Crystallography*
**作者**：Chen L, et al.
**摘要**：利用X射线晶体学解析了PDP重组蛋白的三维结构，揭示了其催化活性中心的关键氨基酸残基，为靶向药物设计提供结构基础。
3. **文献名称**：*Functional Characterization of PDP Recombinant Protein in Cell Signaling Pathways*
**作者**：Wang Y, et al.
**摘要**：通过体外实验证明重组PDP蛋白可调控细胞内cAMP/cGMP水平，影响下游信号通路，提示其在代谢疾病中的潜在作用。
**建议**：实际文献请通过PubMed、Web of Science等平台以关键词“PDP recombinant protein”、“phosphodiesterase domain protein expression”检索，或结合具体研究背景调整检索策略。
**Background of Recombinant Proteins and PDP Applications**
Recombinant proteins are engineered through genetic modification, where target genes are inserted into host organisms (e.g., bacteria, yeast, or mammalian cells) to produce specific proteins. This technology, rooted in recombinant DNA techniques developed in the 1970s, revolutionized biotechnology by enabling large-scale production of proteins with therapeutic, diagnostic, or industrial value. Examples include insulin, monoclonal antibodies, and enzymes used in research and manufacturing.
In recent decades, advancements in expression systems, protein engineering, and purification methods have enhanced the yield, stability, and functionality of recombinant proteins. Platform development projects (PDPs) often focus on optimizing these processes to address challenges like post-translational modifications, scalability, and cost-effectiveness. PDPs may also prioritize proteins for global health, such as vaccines for infectious diseases (e.g., COVID-19 antigens) or treatments for neglected tropical diseases.
A key driver for PDPs is the need for equitable access to biologics. By leveraging open-source technologies or partnerships between academia, industry, and nonprofits, PDPs aim to reduce production barriers and distribute affordable therapies in low-resource settings. Additionally, innovations like CRISPR-based genome editing and AI-driven protein design are accelerating the development of novel recombinant proteins with tailored properties.
Despite progress, challenges persist, including ensuring protein stability, minimizing immunogenicity, and adapting to diverse regulatory frameworks. PDPs often emphasize sustainable practices, such as using eco-friendly expression systems or reducing waste in manufacturing. As demand for biologics grows, recombinant protein PDPs remain critical to advancing precision medicine, pandemic preparedness, and biomanufacturing resilience globally.
×
